Skip to main content

Advertisement

Table 1 Demographic and Clinical Characteristics

From: Psychometric evaluation of the Diabetes Injection Device Experience Questionnaire (DID-EQ) and Diabetes Injection Device Preference Questionnaire (DID-PQ)

Characteristic Total Sample (N = 142) Retest Sample (N = 42)
Age (mean, SD) 63.0 (9.8) 65.1 (8.4)
Gender (n, %)
 Male 62 (43.7%) 19 (45.2%)
 Female 80 (56.3%) 23 (54.8%)
Ethnic background (n, %)
 Hispanic or Latino 4 (2.8%) 2 (4.8%)
 Not Hispanic or Latino 138 (97.2%) 40 (95.2%)
Racial background (n, %)
 Asian 12 (8.5%) 2 (4.8%)
 Black 22 (15.5%) 6 (14.3%)
 Caucasian 107 (75.4%) 32 (76.2%)
 Othera 7 (4.9%) 3 (7.1%)
Marital status (n, %)
 Single 11 (7.7%) 3 (7.1%)
 Married/Living with partner 98 (69.0%) 30 (71.4%)
 Otherb 33 (23.2%) 9 (21.4%)
Employment status (n, %)c
 Full-time work 49 (34.5%) 15 (35.7%)
 Part-time work 7 (4.9%) 1 (2.4%)
 Otherd 86 (60.6%) 26 (61.9%)
Education level (n, %)
 University degree or more 70 (49.3%) 20 (47.6%)
 No university degree 72 (50.7) 22 (52.4%)
Current medication (n, %)f
 Non-insulin injectable medicationg 142 (100.0%) 42 (100.0%)
  Exenatide extended release pen 26 (18.3%) 8 (19.0%)
  Exenatide extended release tray 12 (8.5%) 1 (2.4%)
  Exenatide 13 (9.2%) 4 (9.5%)
  Pramlintide 2 (1.4%) 1 (2.4%)
  Albiglutide 14 (9.9%) 5 (11.9%)
  Dulaglutide 38 (26.8%) 15 (35.7%)
  Liraglutide 38 (26.8%) 8 (19.0%)
 Oral medication 104 (73.2%) 30 (71.4%)
  Blimepiride 16 (11.3%) 6 (14.3%)
  Glipizide 13 (9.2%) 3 (7.1%)
  Canagliflozin 9 (6.3%) 3 (7.1%)
  Metformin 83 (58.5%) 24 (57.1%)
  Other 29 (20.4%) 9 (21.4%)
 Insulin 58 (40.8%) 18 (42.9%)
  Insulin lispro 8 (5.6%) 4 (9.5%)
  Insulin detemir 16 (11.3%) 3 (7.1%)
  Insulin aspart 8 (5.6%) 3 (7.1%)
  Insulin glargine 27 (19.0%) 7 (16.7%)
  Otherh 13 (9.2%) 6 (14.3%)
  1. a Other racial background includes for total sample includes American Indian (n = 2), Euro-American (n = 1), European (n = 1), Hawaiian (n = 2), Pacific Islander (Hawaiian) (n = 1). Other racial background for retest sample includes American Indian (n = 1), Euro-American (n = 1), and Pacific Islander (Hawaiian) (n = 1)
  2. b Other marital status for total sample includes divorced (n = 15), separated (n = 3), widowed (n = 14), and life partner (n = 1). Other marital status for retest sample includes divorced (n = 4), separated (n = 2)
  3. c Not mutually exclusive
  4. d Other for total sample includes employment status includes homemaker/housewife (n = 11), student (n = 2), unemployed (n = 4), retired (n = 80), disabled (n = 9), self-employed (n = 2); self-employed entrepreneur (n = 1); work from home (n = 1). Other for retest sample includes self-employed (n = 1)
  5. 5 Other education status for per protocol sample includes associates degree (n = 3), J.D. (n = 1), R.T license (n = 1), vocational degree – law enforcement certification (n = 1)
  6. e Participants were permitted to list multiple current medications and multiple discontinued medications. Therefore, the sub-rows do not necessarily add to the bolded total rows
  7. f One participant (ID 122–068) reported currently taking two non-insulin injectable medications for treatment of type 2 diabetes (pramlintide and exenatide extended release tray). When completing the DID-EQ, the participant rated pramlintide. When completing the DID-PQ, the participant compared pramlintide (Device 1) and exenatide extended release tray (Device 2)
  8. g Other for total sample includes: pioglitazone (n = 5); dapagliflozin (n = 5); empagliflozin (n = 5); sitagliptin and metformin (n = 4); sitagliptin (n = 3); repaglinide (n = 2); nateglinide (n = 2); glyburide (n = 1); saxagliptin (n = 1); linagliptin (n = 1). Other for retest sample includes: dapaglifozin (n = 2); empagliflozin (n = 2); nateglinide (n = 2); sitagliptin and metformin (n = 1); sitagliptin (n = 1); repaglinide (n = 1)
  9. h Other for total sample includes: Unspecified insulin (n = 5); insulin degludec (n = 3); human insulin (n = 2); insulin glargine (n = 2); insulin glulisine (n = 1). Other for retest sample includes: insulin unspecified (n = 3); human insulin (n = 1); insulin glulisine (n = 1); insulin degludec (n = 1)